AL3818

Phase 3Small molecule

AAdvenchen Laboratories, LLC

AL3818 is one of 85 small molecule programs targeting Cervical Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Alveolar Soft Part SarcomaActive, not recruiting

Cervical CarcinomaPhase 3

Active, not recruiting

Cervical CancerPhase 1/Phase 2

Active, not recruiting

Alveolar Soft Part SarcomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

48 2

Paraplatin

AAvyxa

Phase 3

38 3

Keytruda

Merck & Co.

Phase 3

13 4

Avastin

BBio-Thera Solutions

Phase 3

25 5

Gemzar

Johnson & Johnson

Phase 3

8 6

Camptosar

Pfizer

Phase 3

4 7

Imfinzi

AstraZeneca

Phase 3

1 8

Trexall

Alnylam Pharmaceuticals

Phase 3

1 9

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

4 10

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Interaction

NCT07438886

Q1 2028

Phase 1/2Active, not recruiting

Solid Tumors

NCT04165330

Q4 2028

Phase 3Recruiting

Alveolar Soft Part Sarcoma

NCT03016819

Clinical

Trials by Indication[1]

Cervical Cancer1 trial

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

Terminated·AAdvenchen Laboratories, LLC·Phase 1/2·NCT02558348·12 enrolled

Alveolar Soft Part Sarcoma1 trial

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Recruiting·AAdvenchen Laboratories, LLC·Phase 3·NCT03016819·325 enrolled

Interaction1 trial

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

Not yet recruiting·AAdvenchen Laboratories Nanjing Ltd.·Phase 1·NCT07438886·16 enrolled

Solid Tumors1 trial

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruiting·SSarcoma Oncology Research Center, LLC·Phase 1/2·NCT04165330·56 enrolled

Cervical Carcinoma1 trial

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Unknown status·AAdvenchen Laboratories, LLC·Phase 3·NCT02584478·294 enrolled

1 more indication

Trial1 trial

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Available·AAdvenchen Laboratories, LLC··NCT05612191

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for AL3818. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AL3818 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AL3818. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advenchen Laboratories, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAdvenchen Laboratories, LLC

AL3818

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Cervical Cancer1 trial

Alveolar Soft Part Sarcoma1 trial

Interaction1 trial

Solid Tumors1 trial

Cervical Carcinoma1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News